A) Representative image of myofiber stained for α-BTX (green), Rapsyn (Red) and DAPI (blue). B) Representative images of myofibers in control conditions vs shDHC conditions stained for GFP (green), α-BTX (red), DIC (magenta) and DAPI (blue). C) Western blot with dynein intermediate chain (DIC), p50 and GAPDH antibodies on primary in-vitro differentiated fibers, transfected with shDHC or scramble myofibers. DIC intermediate chain is downregulated while dynactin p50 subunit is not affected. D) Representative images of myofibers stained for Golgi (Giantin), shRNA (GFP) and DAPI (blue). Fine dotted lines show cell periphery and coarse dotted lines represent outline of the Golgi apparatus. Golgi apparatus is dispersed in shDHC transfected cells. E) Quantification of Rapsyn clusters number per fiber and Rapsyn cluster length in control vs shDHC conditions at 2 differentiation time points (days 6 and 9). F) RT-qPCR analysis of AChR gene expression in in-vitro differentiated myofibers after shRNA treatment. Error bars indicate SEM, n=4 G) RT-qPCR analysis of rapsyn gene expression in in-vitro differentiated myofibers after shRNA treatment. Error bars indicate SEM, n=4 H) Timeline of ciliobrevinD washout assay. I) Quantification of Rapsyn clusters number per fiber and Rapsyn cluster length in ciliobrevinD washout assay at 2 differentiation time points (days 6 and 9). Scale bar 10µm.
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Supplementary Figures
Supplementary Figure 1 . Characterization of myofibers in control vs shDHC/ ciliobrevinD conditions. A) Representative image of myofiber stained for α-BTX (green), Rapsyn (Red) and DAPI (blue). B) Representative images of myofibers in control conditions vs shDHC conditions stained for GFP (green), α-BTX (red), DIC (magenta) and DAPI (blue). C) Western blot with dynein intermediate chain (DIC), p50 and GAPDH antibodies on primary in-vitro differentiated fibers, transfected with shDHC or scramble myofibers. DIC intermediate chain is downregulated while dynactin p50 subunit is not affected. D) Representative images of myofibers stained for Golgi (Giantin), shRNA (GFP) and DAPI (blue). Fine dotted lines show cell periphery and coarse dotted lines represent outline of the Golgi apparatus. Golgi apparatus is dispersed in shDHC transfected cells. E) Quantification of Rapsyn clusters number per fiber and Rapsyn cluster length in control vs shDHC conditions at 2 differentiation time points (days 6 and 9). F) RT-qPCR analysis of AChR gene expression in in-vitro differentiated myofibers after shRNA treatment. Error bars indicate SEM, n=4 G) RT-qPCR analysis of rapsyn gene expression in in-vitro differentiated myofibers after shRNA treatment. Error bars indicate SEM, n=4 H) Timeline of ciliobrevinD washout assay. I) Quantification of Rapsyn clusters number per fiber and Rapsyn cluster length in ciliobrevinD washout assay at 2 differentiation time points (days 6 and 9). Scale bar 10µm.
Supplementary Figure 2. Effect of shDHC on AChR clustering genes and muscle differentiation.
A) Representative images of myofibers in ciliobrevinD washout assay stained for dynein intermediate chain (gray) and DAPI (blue). B) Representative images of myofibers in control vs ciliobrevinD-treated conditions stained for α-tubulin (gray) and DAPI (blue). C) Representative images of myofibers in control conditions vs shDHC conditions at day 6 of differentiation stained for GFP (green), alpha-actinin (red) and DAPI (blue). D) Representative images of myofibers in ciliobrevinD washout assay fixed at day 6 of differentiation stained for GFP (green), alpha-actinin (red) and DAPI (blue). E) Representative images of myofibers in in control conditions vs shDHC conditions at day 6 of differentiation stained for GFP (green), MF-20 (gray) and DAPI (blue). F) Representative images of myofibers in ciliobrevinD washout assay fixed at day 6 of differentiation stained for MF-20 (gray) and DAPI (blue). Figure 3 . Characterization of myofiber in ciliobrevinD-treated conditions and in presence of nocodazole. A) RT-qPCR analysis of MuSK gene expression in in-vitro differentiated myofibers after shRNA treatment. Error bars indicate SEM, n=4. B) Representative image of myofiber stained for α-BTX (green), MuSK (Red) and DAPI (blue). Arrow represent AChR and MuSK cluster. C) Representative image of myofiber with or without treatment with nocodazole at day 4 of differentiation (1µg/ml) stained for α-tubulin (gray) and DAPI (blue). D) Representative images of myofibers with or without treatment with nocodazole day 4 of differentiation (1µg/ml) stained for acetylated-tubulin (gray) and DAPI (blue). E) Representative images of myofibers with or without treatment with nocodazole (0.25µg/ml) day 7 of differentiation stained for α-tubulin (gray) and DAPI (blue). F) Representative image of myofiber washed out from nocodazole (0.25µg/ml) day 9 of differentiation stained for BTX (green), MuSK (red), alpha-tubulin (gray) and DAPI (blue). Scale bar 10µm.
Supplementary
Supplementary Figure 4. Comparison between SOD1
G93A vs WT myofibers A) Representative images of WT and SOD1 G93A myofibers at day 6 of differentiation stained for α-BTX (green), MuSK (Red) and DAPI (blue). B) Representative images of WT and SOD1 G93A myofibers at day 6 of differentiation stained for α-BTX (green), phosphoMuSK (Red) and DAPI (blue). Arrow represent AChR and phosphoMuSK cluster. C) Representative images of WT and SOD1 G93A myofibers at day 6 of differentiation stained for α-BTX (green), rapsyn (Red) and DAPI (blue). Scale bar 10µm.
